What’s New in Vaccine Immunology, Part II

What's New in Vaccine Immunology? Getting inoculated with new knowledge, Part II. 

Vaccines are foundational in public health policy because they save millions of lives by preventing/mitigating many infectious diseases caused by bacteria and viruses. With the availability of new technologies and adjuvants, vaccine immunology is rapidly evolving. Clinical immunologists are often called upon to educate colleagues and patients about vaccines. This webinar will provide clinicians with (1) An overview of why and how vaccines work (2) Information regarding the history and current science of vaccines and adjuvants, types of vaccines currently available, and progress and challenges for future vaccines.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Allergists, allied health and other allergy practitioners.

Learning Objectives

After completing this webinar, participants should be able to: 
1.    Explain the role of adjuvants and excipients used in vaccines and address patient concerns
2.    Review the history of vaccine development in the context of public health concerns and re-emerging diseases. 
3.    Utilize vaccine titers in their evaluation of patients with immunodeficiencies. 
4.    Update their knowledge of vaccine immunology in 2024 – where it’s been and where it is going.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 CBRN
Course opens: 
10/09/2024
Course expires: 
10/08/2027
Cost:
$25.00
Rating: 
0

Karla Adams, MD | Karla Adams is an Associate Professor of Pediatrics and a practicing Allergist in San Antonio, Texas. She obtained her medical degree from the Uniformed Services University then completed a Pediatrics residency and Allergy and Immunology Fellowship at the San Antonio Uniformed Services Health Education Consortium in San Antonio, TX. She is currently the Program Director for the Allergy and Immunology Fellowship at Wilford Hall Ambulatory Surgical Center, San Antonio, TX

Joel Brooks, DO, MPH | Joel Brooks is an Assistant Professor of Pediatrics at the Columbia University Vagelos College of Physicians and Surgeons where he serves as the Associate Program Director of their Allergy and Immunology Fellowship Program. He also helps lead several committees for the American College of Allergy, Asthma, and Immunology and American Academy of Allergy, Asthma, and Immunology, including their Vaccine Committee.

Niraj C. Patel, MD, MS | Niraj C. Patel  is an Associate Professor of Pediatrics, Allergy and Immunology. He is an immunologist who treats primary immunodeficiencies in children and adults. His patient population includes those with recurrent infections and fevers, drug allergies, and secondary immunodeficiencies. He is board certified with the American Board of Allergy & Immunology and American Board of Pediatric Infectious Diseases. He is currently a Pediatric Allergy and Immunology Specialist at Duke University Medical Center, Durham, NC.

Dipa K. Sheth, MD | Dipa K. Sheth is an Assistant Professor of Medicine at George Washington University as well as the Uniformed Health Services University of the Health Sciences. She received her medical degree from George Washington University School of Medicine. She is board certified in allergy and immunology by the American Board of Allergy Immunology and is a fellow of the ACAAI and AAAAI. Her specialty is allergy & immunology. Her subspecialties are severe asthma, drug allergy, and eczema. .

All identified relevant financial relationships with ineligible companies have been mitigated.

Joel Brooks, DO, MPH | Moderator, Planner
Karla Adams, MD | Faculty, Planner
Niraj C. Patel, MD, MS | Faculty
Dipa K. Sheth, MD | Faculty, Planner
Joel Klein, MD | Planner

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
  • 1.00 CBRN

Price

Cost:
$25.00
Please login or create an account to take this course.